Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen

NCT00088660 is registered in ClinicalTrials.gov with Therion Biologics Corporation as lead sponsor.

NCT NCT00088660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00088660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen
Lead sponsor
Therion Biologics Corporation
Phase
Phase 3
Overall status
Unknown status
Start date
June 30, 2004
Completion date
Not reported
Enrollment
250
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer